AbbVie has filed for approval of its therapy for Parkinson's disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current drugs that often fail to
Considerable scientific progress across neurological diseases and disorders was reported at the recent 74th American Academy of Neurology (AAN) Annual Meeting.
Biogen has licensed rights to a digital therapeutic (DTx) developed by MedRhythms which combines sensors, software, and music to help people with multiple sclerosis tackle mobility problems
The US FDA has authorised a new test that can detect amyloid plaques in early-stage Alzheimer's disease without the use of PET scans, which expose patients to radiation.
Biogen has given up on seeking approval for its Alzheimer's disease therapy Aduhelm in the EU, saying that discussions with EU regulators had made it clear the current data for the drug is
Diagnosing Parkinson's in the earliest stages before symptoms become serious is a major challenge in medicine, and digital health company PreciseDx thinks it may have a solution to the pro
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.